BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20171968)

  • 1. Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy.
    Rasmussen AM; Borelli G; Hoel HJ; Lislerud K; Gaudernack G; Kvalheim G; Aarvak T
    J Immunol Methods; 2010 Apr; 355(1-2):52-60. PubMed ID: 20171968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
    Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
    Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
    Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
    Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy.
    Feuchtinger T; Lang P; Hamprecht K; Schumm M; Greil J; Jahn G; Niethammer D; Einsele H
    Exp Hematol; 2004 Mar; 32(3):282-9. PubMed ID: 15003314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.
    Zappasodi R; Di Nicola M; Carlo-Stella C; Mortarini R; Molla A; Vegetti C; Albani S; Anichini A; Gianni AM
    Haematologica; 2008 Oct; 93(10):1523-34. PubMed ID: 18728033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
    Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
    Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.
    Oelke M; Moehrle U; Chen JL; Behringer D; Cerundolo V; Lindemann A; Mackensen A
    Clin Cancer Res; 2000 May; 6(5):1997-2005. PubMed ID: 10815925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation.
    Feuchtinger T; Richard C; Joachim S; Scheible MH; Schumm M; Hamprecht K; Martin D; Jahn G; Handgretinger R; Lang P
    J Immunother; 2008; 31(2):199-206. PubMed ID: 18481389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
    Bristol JA; Schlom J; Abrams SI
    Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
    Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
    J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.
    Ruby CE; Redmond WL; Haley D; Weinberg AD
    Eur J Immunol; 2007 Jan; 37(1):157-66. PubMed ID: 17183611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
    Rolle CE; Carrio R; Malek TR
    Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
    Butler MO; Lee JS; Ansén S; Neuberg D; Hodi FS; Murray AP; Drury L; Berezovskaya A; Mulligan RC; Nadler LM; Hirano N
    Clin Cancer Res; 2007 Mar; 13(6):1857-67. PubMed ID: 17363542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient induction and expansion of human alloantigen-specific CD8 regulatory T cells from naive precursors by CD40-activated B cells.
    Zheng J; Liu Y; Qin G; Chan PL; Mao H; Lam KT; Lewis DB; Lau YL; Tu W
    J Immunol; 2009 Sep; 183(6):3742-50. PubMed ID: 19684082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-15 favors the expansion of central memory CD8+ T cells in ex vivo generated, antileukemia human cytotoxic T lymphocyte lines.
    Daudt L; Maccario R; Locatelli F; Turin I; Silla L; Montini E; Percivalle E; Giugliani R; Avanzini MA; Moretta A; Montagna D
    J Immunother; 2008 May; 31(4):385-93. PubMed ID: 18391757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD8+CD45RA+CD27-CD28-T-cell subset in PBL of cervical cancer patients representing CD8+T-cells being able to recognize cervical cancer associated antigens provided by HPV 16 E7.
    Pilch H; Hoehn H; Schmidt M; Steiner E; Tanner B; Seufert R; Maeurer M
    Zentralbl Gynakol; 2002; 124(8-9):406-12. PubMed ID: 12655469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells.
    Xia G; He J; Zhang Z; Leventhal JR
    Transplantation; 2006 Dec; 82(12):1749-55. PubMed ID: 17198271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effector CD8+ T cells activated in vitro confer immediate and long-term tumor protection in vivo.
    Perret R; Ronchese F
    Eur J Immunol; 2008 Oct; 38(10):2886-95. PubMed ID: 18825745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer.
    Jorritsma A; Bins AD; Schumacher TN; Haanen JB
    Cancer Res; 2008 Apr; 68(7):2455-62. PubMed ID: 18381454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
    Kilinc MO; Gu T; Harden JL; Virtuoso LP; Egilmez NK
    J Immunol; 2009 Apr; 182(7):4217-25. PubMed ID: 19299720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.